Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients | Zendy

C. Charpentier | Zendy; Lucile Larrouy | Zendy; Benoît Visseaux | Zendy; Roland Landman | Zendy; M. Levittas | Zendy; Alexandre Storto | Zendy; Florence Damond | Zendy; Yazdan Yazdanpanah | Zendy; P. Yéni | Zendy; Françoise BrunVézinet | Zendy; Diane Descamps | Zendy

Open Access

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients

Author(s) -

C. Charpentier,

Lucile Larrouy,

Benoît Visseaux,

Roland Landman,

M. Levittas,

Alexandre Storto,

Florence Damond,

Yazdan Yazdanpanah,

P. Yéni,

Françoise BrunVézinet,

Diane Descamps

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks067

Subject(s) - in vitro , human immunodeficiency virus (hiv) , medicine , drug resistance , virology , biology , microbiology and biotechnology , genetics

BMS-626529 is a member of the new drug class of HIV-1 attachment inhibitors currently in development. Mutations selected during in vitro experiments with BMS-626529 are located in the gp120 region: L116P, A204D, M426L, M434I-V506M and M475I. A differential antiviral activity of BMS-626529 was observed depending of the viral subtype. The aim of our study was to assess the prevalence of subtype-related polymorphisms previously described as being associated with in vitro resistance to BMS-626529 in patients infected with different HIV-1 'non-B' subtypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research